NHS Dumfries & Galloway Ferrous Salt Review Protocol November 09

Similar documents
Product Cost per Pack Cost per 28 days (assuming 2 sprays od) Flixonase years 50mcg in both nostrils od (increasing to max bd prn)

Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015

Immediate Release Nifedipine Review July 2011

NHS Dumfries & Galloway Erectile Dysfunction Audit October 2010

NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)

Management of Migraine

Fencino patch (5) 2. Check the practice has agreed to the protocol and a signed copy is in place.

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

Asacol / Mesalazine to Octasa Switch protocol

PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation

Metformin MR to low cost branded generic (Sukkarto SR) Switch Protocol

Ref. Version Supersedes Approved for Date approved Document Owner N/A MMT 17/01/2017 Lois Taylor. Switching to Alogliptin (Vipidia )

Review of bisphosphonate prescribing May 2014

Northern Treatment Advisory Group

Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW

Costing statement: chronic idiopathic constipation - Lubiprostone

Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit:

West Suffolk Clinical Commissioning Group (WSCCG) Safety audit for methotrexate prescribing for patients in primary care

Medicines Optimisation Team Standard Operating Procedure Insulin Quantities Audit

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

The Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.

A new model for prescribing varenicline

Optimising Insulin Pen Needles

SHARED CARE PRESCRIBING GUIDELINE

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

Guidance on Bulk Prescribing for Care Home Patients

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

NHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

Purpose of the Guideline

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

IMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY

Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs

Practice Name. Audit Undertaken By and Job Title. Date of Audit

HYDROXYCARBAMIDE for Haematological conditions (Adults)

Chemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers

Unit 204 Assist with the assembly of prescribed items

Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant

This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are:

Developed By Name Signature Date

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Policy for the safe use of oral methotrexate

Review of Oral Nutritional Supplement (ONS) prescribing

SHARED CARE PRESCRIBING GUIDELINE

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

PRESCRIBING SUPPORT TEAM AUDIT: ACE Inhibitors in the treatment of stable angina (October 2007) PRESCRIBING SUPPORT TECHNICIAN:

Prescribing Guidelines on Gluten-Free products. Information for GPs

Appropriate Use of Prescribed Oral Nutritional Supplement (ONS) in the Community

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008

Guidance on Bulk Prescribing for Care Home Residents

PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)

PATIENT GROUP DIRECTION PROCEDURE

GPMP and TCA Coeliac disease

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013

Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy

ProScript User Guide. Pharmacy Access Medicines Manager

Developed By Name Signature Date

GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018)

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

SULFASALAZINE (Adults)

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

PATIENT GROUP DIRECTION

Vitamin and Mineral Supplementation and Monitoring. Bariatric Surgery

Ketorolac injection. Supportive care

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Shared Care Agreement for Donepezil

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.

Care homes - Homely remedies

DETECTION, INVESTIGATION AND MANAGEMENT OF ANAEMIA

Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules

PATIENT GROUP DIRECTION

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Medicines Optimisation Prescribing Audit: Long acting muscarinic antagonist (LAMA ) review

Prescribing Guidelines for Oral Nutritional Supplements (ONS) for adults

Care Homes - Homely Remedies Protocol

The prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics

Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children

Care homes - Homely remedies

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention

Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients

Patient Group Directions (PGDs)

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists

Understanding the Benefits and Risks

Hydroxychloroquine (Adults)

Transcription:

Title of Project: NHS Dumfries & Galloway Ferrous Salt Review Protocol November 09 1 Reason for the review Choice of iron preparation is based on cost and incidence of side effects (BNF). There is little difference in efficiency of absorption of iron between the different salts. Modified release preparations have no therapeutic advantage and the low incidence of side effects are related to the lower absorption of iron. Side effects include nausea, constipation and diarrhoea but can usually be managed by dose reduction. Ferrous fumarate in the form of Fersaday or Galfer are the most cost-effective choices of iron preparation. Iron salts should be given orally until haemoglobin has reached reference range and then maintained for 3 months, to replenish iron stores, before stopping (BGS guidelines). The review will identify patients suitable for stopping therapy as well as those suitable for switching to a more cost effective preparation Iron preparation Cost of therapeutic dose (28 days) Cost of prophylactic dose (28 days) Ferrous sulphate 200mg tablets 200mg tds ( 4.36) 200mg od ( 1.44) Ferrous fumarate 305mg caps (Galfer) Ferrous fumarate 322mg tabs (Fersaday) Ferrous fumarate 210mg tabs (Fersamal) Ferrous gluconate 300mg One cap twice daily ( 1.00) One tablet twice daily ( 1.58) Two tablets three times a day ( 2.44) 4-6 tablets daily in divided doses ( 4.32 6.48) One capsule daily (50p) One tablet daily (79p) One tablet twice daily (81p) Two tablets daily ( 2.16) 2 Inclusion Criteria Search for all patients prescribed any iron preparation on repeat prescription within the last 6 months. Record last haemoglobin result and ferritin against lab reference range specified. (Ferritin levels may be raised in liver inflammation therefore CRPs and LFTs should normally be taken and if these are raised the ferritin may be falsely high) Patients whose haemoglobin, ferritin, CRP and LFTs are normal range would be suitable for discontinuation of iron replacement therapy (BGS Guidelines) Caution with patients suffering from inflammatory bowel disease, intestinal strictures and diverticular disease as oral iron can exacerbate diarrhoea not an exclusion, but may benefit from careful dose titre. 3 Exclusion Criteria Previous intolerance to ferrous fumarate. Compliance issues refer to GP Patients with terminal cancer Previous switch to an alternative product which caused distress Any individual patient exclusions deemed necessary by the GP. (e.g. patients who are deemed to be not open to change, as judged by the GP) 4 Preparation and planning Implementation of audit in selected GP practices Prescribing Support Team is as follows: Protocol to be discussed with all GPs in the practice to ensure that agreement to proceed is reached Computer search of all patients according to the inclusion criteria

5 Action Review of patients medical notes and repeat prescribing records Two lists produced: o o List of patients on an iron preparation who are eligible to switch to more cost effective alternative List of patients for whom there is no longer a valid indication for receiving iron salts (Haemoglobin, Ferritin, CRP and LFTs all normal range check local laboratory reference values). Inform GP to arrange medication to be stopped. List of eligible patients to be checked by GP/GPs Letters to be sent to eligible patients and switch or stop to be undertaken on the computer system (Appendix 1 and 2) Letters written to all patients outlining the reasons for the switch or stopping to ensure they are fully informed and given an opportunity to discuss the switch with either their GP or practice pharmacist. (Appendix 1 and 2) Admin staff in practices to be made aware of changes of repeat medication. Local pharmacies to be informed of need to reduce stock and of counselling for patients (copy of patient letters supplied) Report for practices will include number of switches made by the pharmacist/technician and projected cost savings as a result of the recommendations. Reference: British Gastroenterology Society Guidelines for the management of iron deficiency anaemia. June 2000. Review to be undertaken by: GP Authorisation: Date:

Appendix 1: Patient letter if stopping iron preparation. Patient name Address Dear Mr/Mrs As part of a review of prescribing, NHS Dumfries and Galloway are currently reviewing all patients prescribed iron supplements for the treatment or prevention of iron-deficient anaemias. Iron is given to allow your haemoglobin to get to a normal level in the body. Iron should be given for at least 3 months to allow your body to replenish its iron stores, but after this time it is safe to stop, as long as your haemoglobin had reached a normal level. We have identified that you no longer need to continue taking your iron supplement after you have finished your current pack of treatment and have therefore removed it from your repeat medication list, with your doctor s approval. This change has been made to ensure that people are not taking medicines unnecessarily and it also helps doctors to make the most effective use of available resources. Should have any queries, please contact the Surgery on the number above or, alternatively, you can contact a member of the Prescribing Support Team on Yours sincerely Name Prescribing Support Technician On behalf of the Doctors

Appendix 2: Patient letter if changing iron preparation. Patient name Address Dear Mr/Mrs As part of a review of prescribing, NHS Dumfries and Galloway are currently reviewing all patients prescribed the iron supplement, ferrous sulphate for the treatment or prevention of iron-deficient anaemias. The next time you request ferrous sulphate tablets you will notice we have changed your prescription to ferrous fumarate tablets. Ferrous fumarate gives you more iron per tablet, therefore you don t need to take as many. It still provides your body with the required amount of iron needed to boost your iron stores. This change has been made to help doctors to continue to use high quality treatments while making the most effective use of available resources. We propose to introduce the change with your next prescription. Please finish your tablets as normal and then start the new tablets as directed. Should have any queries, please contact the Surgery on the number above or, alternatively, you can contact a member of the Prescribing Support Team on Yours sincerely Name Prescribing Support Technician On behalf of the Doctors

Ferrous Salt Review Project - Audit Data Collection Sheet SURGERY: DATE: UNDERTAKEN BY: Patients name/dob Prescribed medication and dosage Indication Compliance Proposed change Hb & Ferritin level and date Previous intolerance to ferrous fumarate Excluded from change GP Actioned approved